This cohort study aimed to compare the effectiveness and cost-effectiveness of metabolic bariatric surgery (MBS) with GLP-1 receptor agonists (GLP-1 RAs) in patients with class II or III obesity. The researchers utilized a large U.S. insurance claims database to assess weight loss outcomes and associated healthcare costs. The study period spanned from July 2024 to July 2025, focusing on patients with a body mass index (BMI) of 40 or greater to ensure comparability between the two treatment groups.

The study included a total of 30,458 patients, with 14,101 undergoing MBS and 16,357 receiving GLP-1 RAs. The primary outcome measures were total weight loss and total healthcare costs over a two-year period. Secondary outcomes included the incidence of obesity-related comorbidities and the need for additional interventions. Data analysis was performed using multivariate regression models to adjust for potential confounders such as age, sex, baseline BMI, and presence of comorbid conditions.

The study found that patients who underwent MBS experienced a mean total weight loss of 28.3%, compared to 10.3% in the GLP-1 RA group. Additionally, the MBS group had a mean reduction in total healthcare costs of $11,689 over the two-year period, whereas the GLP-1 RA group incurred an increase in costs of $2,689. These findings suggest that MBS not only provides greater weight loss but also offers a more cost-effective long-term solution for patients with severe obesity.

The results of this study have significant implications for clinical practice. While GLP-1 RAs have emerged as a popular pharmacological option for weight management, their effectiveness may be limited in patients with higher degrees of obesity. MBS, on the other hand, offers more substantial and sustained weight loss, which could lead to a reduction in obesity-related comorbidities such as type 2 diabetes, hypertension, and sleep apnea. Furthermore, the cost savings associated with MBS could alleviate the financial burden on healthcare systems.

For medical students and healthcare professionals, this study underscores the importance of considering surgical options in the management of patients with severe obesity, particularly when pharmacological treatments alone may not suffice. It also highlights the need for a multidisciplinary approach to obesity treatment, involving collaboration between endocrinologists, surgeons, dietitians, and psychologists to optimize patient outcomes.

One limitation of the study is its observational design, which may introduce selection bias. Patients who opt for surgery may differ in characteristics from those who choose pharmacological treatment, potentially influencing the outcomes. Additionally, the study’s reliance on insurance claims data may not capture all relevant clinical information, such as detailed laboratory results or patient-reported outcomes. Future research should aim to conduct randomized controlled trials to confirm these findings and explore the long-term effects of MBS compared to GLP-1 RAs in diverse patient populations.

Share this post